Skip to main content
Amir Kashani, MD, Ophthalmology, Baltimore, MD, Johns Hopkins Hospital

AmirHosseinKashaniMDPhD

Ophthalmology Baltimore, MD

Retinal Disease

Associate Professor of Ophthalmology, Wilmer Eye Institute of the Johns Hopkins University

Dr. Kashani is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Kashani's full profile

Already have an account?

Education & Training

  • University of Southern California/LAC+USC Medical Center
    University of Southern California/LAC+USC Medical CenterResidency, Ophthalmology, 2007 - 2010
  • Johns Hopkins University
    Johns Hopkins UniversityInternship, Internal Medicine, 2006 - 2007
  • Johns Hopkins University School of Medicine
    Johns Hopkins University School of MedicineClass of 2006

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2007 - 2025
  • MD State Medical License
    MD State Medical License 2020 - 2024
  • MI State Medical License
    MI State Medical License 2011 - 2015
  • American Board of Ophthalmology Ophthalmology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Original Article Suspended Scattering Particles in Motion: A Novel Feature of OCT Angiography in Exudative Maculopathies  
    Philip J Rosenfeld, Amir H Kashani, Kyle M Green, Julie Kwon, K Bailey Freund, David Sarraf, Nadia K Waheed, Carl B Rebhun, ScienceDirect

Press Mentions

  • First U.S. Patient Receives Autologous Stem Cell Therapy to Treat Dry AMD
    First U.S. Patient Receives Autologous Stem Cell Therapy to Treat Dry AMDSeptember 2nd, 2022
  • First US Patient Gets Autologous Stem Cell Therapy to Treat Dry AMD
    First US Patient Gets Autologous Stem Cell Therapy to Treat Dry AMDSeptember 1st, 2022
  • Regenerative Patch Technologies Presents Clinical Data Demonstrating Long-Term Survival and Function of an Allogenic Bioengineered Cellular Implant in Patients with Advanced Dry Aged-Related Macular Degeneration
    Regenerative Patch Technologies Presents Clinical Data Demonstrating Long-Term Survival and Function of an Allogenic Bioengineered Cellular Implant in Patients with Advanced Dry Aged-Related Macular DegenerationFebruary 4th, 2022
  • Join now to see all

Hospital Affiliations